Lund, Sweden-based Active Biotech AB is to let go 84% of its workforce following the termination of a Phase 3 clinical programme for a prostate cancer drug that was shown to delay disease progression, but did not extend overall survival. The drug, tasquinimod, was being developed with Ipsen SA.
